Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Nilvadipine Is Effective for Chronic Schizophrenia in a Double-Blind Placebo-Controlled Study

Yamada, Kazuo MD; Kanba, Shigenobu MD, PhD; Ashikari, Iyoko MD; Ohnishi, Kimio MD; Yagi, Gohei MD, PhD; Asai, Masahiro MD, PhD

Journal of Clinical Psychopharmacology: December 1996 - Volume 16 - Issue 6 - p 437-439

We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study. The total scores of the Brief Psychiatric Rating Scale decreased significantly when the patients were on nilvadipine compared with placebo. Improvement was particularly significant in emotional withdrawal and uncooperativeness. Nilvadipine was not effective, however, for tardive dyskinesia. No adverse effects, such as hypotension, occurred. (J Clin Psychopharmacol 1996;16:437-439).

(Yamada, Ashikari, Ohnishi, Yagi, Asai) Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan; (Yamada, Ashikari) Department of Neuropsychiatry, Jiundou-Naika Hospital, Tokyo, Japan; and (Kanba) Department of Neuropsychiatry, Yamanashi Medical University, Yamanashi, Japan.

Received November 14, 1995; accepted after revision April 12, 1996.

Address requests for reprints to: Shigenobu Kanba, MD, Department of Neuropsychiatry, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakakoma-gun, Yamanashi, 409-38, Japan.

© Williams & Wilkins 1996. All Rights Reserved.